Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Treatment Resistant FSGS
NCT01573533Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Oct 2013
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of rituximab in focal segmental glomerulosclerosis (FSGS), sponsored by Mayo Clinic. Started Oct 2013; status: completed.
02
Drugs
rituximab
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT01573533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01573533.